ロード中...
The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK(+) non–small‐cell lung cancer who have progressed on or are intolerant to crizotinib. A clinical study was conducted to asses...
保存先:
| 出版年: | Clin Pharmacol Drug Dev |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767012/ https://ncbi.nlm.nih.gov/pubmed/30570839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.641 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|